

TIMOTHY M. CLARK (Bar No. 284447)
tclark@thesandersfirm.com
LAUREN A. WELLING (Bar No. 291813)
lwelling@thesandersfirm.com
SANDERS PHILLIPS GROSSMAN, LLC
2860 Michelle Drive, Suite 220
Irvine, CA 92606
Telephone: +1 877 480 9142
Facsimile: +1 213 330 0346

Attorneys for Plaintiffs

DONALD F. ZIMMER, JR. (Bar No. 112279)
fzimmer@kslaw.com

WILLIAM E. STEIMLE (Bar No. 203426)
wsteimle@kslaw.com

KING & SPALDING LLP

101 Second Street, Suite 2300

San Francisco, CA 94105

Telephone: +1 415 318

Facsimile: +1 415 318 1300

Attorneys for Defendants

BRISTÖL-MYERS SQUIBB C

ASTRAZENECA PHARMACEUTICALS LP,
and MCKESSON CORPORATION

IN THE UNITED STATES DISTRICT COURT

FOR THE NORTHERN DISTRICT OF CALIFORNIA

CAROLYN WILLIAMS, an individual, et al.,

Case No.: 3:16-CV-07152-JST

Plaintiffs,

V.

ASTRAZENECA PHARMACEUTICALS
LP, et al.,

**STIPULATION FOR ORDER TO
CONTINUE DEADLINE TO SUBMIT
PROPOSED ORDERS PURSUANT TO
N.D. CAL. CIV. L.R. 6-1**

Judge: Honorable Jon S. Tigar

Defendants.

AND RELATED ACTION:

Michael Martin, et al. v. AstraZeneca Pharmaceuticals LP, et al.,
Case No. 4:17-cv-00661-JST;

WHEREAS, at the July 12, 2017 Case Management Conference, the Court ordered that the parties submit (a) a proposed protective order, (b) a proposed order regarding claims of

**STIPULATION FOR ORDER TO CONTINUE DEADLINE TO SUBMIT PROPOSED ORDERS
PURSUANT TO N.D. CAL. CIV. L.R. 6-1 - 3:16-CV-07152-IST**

1 privilege, and (c) a proposed order governing the production of Electronically Stored
2 Information in the above-entitled and related-action by Friday, August 4, 2017;

3 WHEREAS, at the July 12, 2017 Case Management Conference, Defendants raised the
4 issue that the Court may not have subject matter jurisdiction over these claims in light of the
5 Court's rulings remanding the related actions *Okoye, et al. v. Bristol-Myers Squibb Company, et*
6 *al.* Case No. 3:17-cv-00668-JST [Doc. 24] and *Leedy, et al. v. Bristol-Myers Squibb Company, et*
7 *al.* Case No. 3:16-cv-07269-JST [Doc. 36];

8 WHEREAS, the parties are meeting and conferring regarding the issue of subject-matter
9 jurisdiction, and how best to raise that issue with the Court;

10 WHEREAS, the above-entitled and related-action are the only remaining related actions
11 before the Court;

12 WHEREAS, the parties believe that it would benefit judicial economy and efficiency to
13 address the issue of subject-matter jurisdiction before submitting the above-described proposed
14 orders, because if the Court lacks jurisdiction, any further efforts of the Court and the parties
15 would be wasted;

16 **NOW, THEREFORE, the Parties stipulate as follows:**

17 The August 4, 2017 deadline by which the parties are to submit the above-described
18 proposed orders be continued to August 18, 2017.

19 **IT IS SO STIPULATED.**

20 DATED: August 4, 2017

SANDERS PHILLIPS GROSSMAN, LLC

21
22 By: /s/ Lauren Welling
23 Timothy M. Clark
24 Lauren Welling
Attorneys for Plaintiffs

1 DATED: August 4, 2017

KING & SPALDING LLP

3 By: /s/ William E. Steimle
4 Donald F. Zimmer, Jr.
5 William E. Steimle
6 Attorneys for Defendants

7 **Signature Attestation (N.D. Cal. L.R. 5-1(i)(3))**

8 I, Lauren Welling, attest that concurrence in the filing of this document has been obtained
9 from each signatory whose ECF user ID and password are not being used in the electronic filing
10 of this document.

11
12 Having considered Plaintiffs' and Defendants AstraZeneca Pharmaceuticals LP, Bristol-
13 Myers Squibb Company, and McKesson Corporation's (collectively, the Parties') Stipulation for
14 Order to Continue the August 4, 2017 deadline by which the parties are to submit the above-
15 described proposed orders, and good cause appearing, the Parties' Stipulation is **GRANTED**.

16 The August 4, 2017 deadline to submit proposed orders is continued to August 18, 2017.
17

18 **IT IS SO ORDERED.**

19
20 DATED: August 7, 2017 _____

21
22 
HONORABLE JON S. TIGAR
United States District Judge